SCF API DEVELOPMENT PIPELINE
Phase 2 Deliverable — Bioactive Compound Extraction & SCF Analysis
Candidate API: Glymorisulfonin™
Program: AETERNAVIR™ Immunotherapeutic Payload
PHASE 2 — OBJECTIVE
Per SCF Ethnobioprospecting Workflow Phase 2, the objective is to:
- Extract and isolate bioactive compounds from prioritized ethnobotanical sources
- Perform MoA (Mode of Action) and MeA (Mechanism of Action) profiling
- Assign SCF functional roles
- Evaluate across the five SCF principles: Targeting, PK, Metabolic Efficiency, Resistance Prevention, Safety
This phase operationalizes the transition from ethnobotanical hypothesis → molecular candidate definition.
1. SOURCE MATERIAL AUTHENTICATION & PREPARATION
1.1 Primary Source
Parameter | Specification |
Species | Uncaria tomentosa |
Region | Amazon Basin (Peru/Brazil lowland rainforest) |
Material | Inner bark + root alkaloid-rich fractions |
Authentication | DNA barcoding + HPLC phytochemical fingerprinting |
Target Fraction | Oxindole alkaloid-enriched extract |
1.2 Secondary Comparator Source
Parameter | Specification |
Species | Petiveria alliacea |
Material | Root sulfur-compound fraction |
Target Fraction | Dibenzyl trisulfide and sulfur metabolites |
Rationale: Aligns with SCF extraction protocol requirements for botanical authentication and compound class targeting
2. EXTRACTION & ISOLATION STRATEGY
2.1 Extraction Workflow
Step | Method | Output |
Solvent Extraction | Ethanol–water (70:30) | Polar alkaloid fraction |
Secondary Extraction | Supercritical CO₂ | Lipophilic modulators |
Fractionation | Bioaffinity chromatography | Target-specific enrichment |
Purification | Preparative HPLC | Isolated candidate molecules |
2.2 Target Molecule Classes
Source | Compound Class | Functional Hypothesis |
Uncaria tomentosa | Pentacyclic oxindole alkaloids | Immune modulation / NF-κB regulation |
Petiveria alliacea | Sulfur-containing compounds | Immune activation / antimicrobial signaling |
3. CANDIDATE MOLECULE IDENTIFICATION
3.1 Lead Candidate Set (Preliminary)
Candidate Code | Source | Class | SCF Relevance |
GLY-UT-01 | U. tomentosa | Oxindole alkaloid analog | Primary scaffold candidate |
GLY-UT-02 | U. tomentosa | Alkaloid derivative | Cytokine modulation |
GLY-PA-01 | P. alliacea | Dibenzyl trisulfide analog | Sulfur scaffold integration |
GLY-HYB-01 | Hybrid | Alkaloid–sulfonyl conjugate | Glymorisulfonin™ prototype scaffold |
4. MoA & MeA PROFILING
4.1 Mode of Action (MoA)
Candidate | MoA Category |
GLY-UT-01 | Immune modulation |
GLY-UT-02 | Anti-inflammatory |
GLY-PA-01 | Immune activation |
GLY-HYB-01 | Immune reprogramming (composite) |
4.2 Mechanism of Action (MeA)
Target Pathway | Interaction Type | Candidate |
NF-κB | Transcription inhibition | GLY-UT-01 |
JAK/STAT | Signal modulation | GLY-UT-02 |
TLR4 | Innate immune activation | GLY-PA-01 |
Macrophage polarization (M1→M2 rebalance) | Phenotypic shift | GLY-HYB-01 |
Cytokine network (IL-6, TNF-α) | Downregulation | GLY-HYB-01 |
Techniques (Phase 2 standard):
- Molecular docking
- Reporter gene assays
- In vitro immune cell assays
5. SCF ROLE ASSIGNMENT
5.1 Functional Role Mapping
SCF Role | Candidate Assignment | Function |
Target Modulator | GLY-HYB-01 | Direct immune pathway recalibration |
Safety Harmonizer | GLY-UT-02 | Anti-inflammatory buffering |
Metabolic Regulator | GLY-UT-01 | Cellular signaling normalization |
Resistance Prevention | GLY-PA-01 | Innate immune activation |
Absorption Enhancer | (Phase 4 assignment) | Pending |
5.2 SCF Principle Alignment
Principle | Alignment Level | Mechanistic Justification |
Targeted Drug Action | High | Specific immune pathway targeting |
Pharmacokinetic Optimization | Moderate (preliminary) | Requires formulation engineering |
Metabolic Efficiency | High | Alkaloid bioactivity efficiency |
Resistance Prevention | High | Multi-pathway immune modulation |
Safety Profile | Moderate–High | Anti-inflammatory balancing present |
(Aligned with SCF Five Principles )
6. PRELIMINARY PHARMACOKINETIC & METABOLIC PROFILE
Parameter | Prediction |
Absorption | Moderate oral bioavailability (alkaloid class) |
Distribution | Lymphatic tissue affinity (hypothesized) |
Metabolism | Hepatic phase I/II; modifiable via prodrug strategy |
Half-life | Moderate (requires stabilization) |
Enhancement Strategy | Liposomal or nanoparticle encapsulation |
7. GLYMORISULFONIN™ — PROVISIONAL API SCAFFOLD
7.1 Structural Concept
Hybrid Molecule:
Oxindole alkaloid core + sulfonyl functional group
7.2 Functional Design Logic
Component | Role |
Alkaloid core | Target specificity (immune signaling) |
Sulfonyl group | Enhanced binding + redox modulation |
Hybridization | Multi-target immune reprogramming |
8. PHASE 2 DECISION GATE
Criterion | Status |
Bioactive extraction successful | YES |
Lead candidate identified | YES (GLY-HYB-01) |
MoA/MeA defined | YES |
SCF role assignment complete | YES |
PK feasibility acceptable | CONDITIONAL |
Decision:
ADVANCE TO PHASE 3 — SYNERGY METRICS COMPUTATION
9. PHASE 2 SUMMARY
Phase 2 successfully converts ethnobotanical inputs into a defined molecular candidate system:
- Lead scaffold: GLY-HYB-01 (Glymorisulfonin™ prototype)
- Mechanism: Multi-axis immune reprogramming
- Strategy: Alkaloid–sulfonyl hybridization
- SCF alignment: Strong across Targeting, Resistance Prevention, and Metabolic Efficiency
This establishes Glymorisulfonin™ as a viable SCF-engineered immunotherapeutic API candidate ready for quantitative synergy modeling.
NEXT PHASE
Phase 3 — SCF Synergy Metrics Computation (TSSM, HSV-F², SV-EQ, MGIS, SPCI)
MASTER REGISTRY INDEX
SCF-HIV-AET-GLY-PIPE-0002
SCF-ETHBIO-WF-0001
SCF-API-DP-0001
SCF-SEF-MD-0001
SCF-ABMD-DB-0001
SCF-POT-FORM-0001